布地奈德/福莫特罗联合噻托溴铵治疗稳定期慢性阻塞性肺疾病疗效观察

Curative Effect Observation of Budesonide/Formoterol Combined with Tiotropium Bromide on Chronic Obstructive Pulmonary Disease on the Stable Phase

目的:探讨布地奈德/福莫特罗联合噻托溴铵用于稳定期慢性阻塞性肺疾病(COPD)的疗效。方法:80例稳定期COPD患者随机分为观察组与对照组各40例。两组患者均予常规治疗。对照组予布地奈德/福莫特罗粉吸入剂160μg/4.5μg,吸入治疗bid;观察组在对照组基础上加用噻托溴铵粉吸入剂18μg,吸入治疗qd。两组均连用3个月。观察并记录两组患者治疗前后肺功能、动脉血气指标和临床症状评分变化,比较两组治疗中不良反应发生情况。结果:治疗3个月后,两组患者FEV1、FEV1%、FEV1/FVC均较治疗前明显上升(P<0.05或P<0.01),且观察组FEV1、FEV1%上升幅度大于对照组(P<0.05)。两组患者Pa O2较前明显上升,Pa CO2较前明显下降(P<0.05或P<0.01),且观察组改善幅度大于对照组(P<0.05)。两组患者CAT评分均较前明显下降(P<0.05或P<0.01),且观察组下降幅度大于对照组(P<0.05)。两组药品不良反应发生率比较无明显差异(P>0.05)。结论:布地奈德/福莫特罗与噻托溴铵联合治疗稳定期COPD具有协同作用,能明显改善患者肺功能与临床症状,且不良反应少,安全性佳。

Objective： To discuss curative effect of budesonide/formoterol combined with tiotropium bromide on chronic obstructive pulmonary disease （COPD） on the stable phase. Methods：80 cases of patients with COPD on the stable phrase were divided into observation group and control group at random, with 40 cases of patients in either group. The patients in two groups were given routine medical treatment for COPD on the stable phrase. The patients in control group were given budesonide/formoterol inhalation for 160μg/4.5 μg per time, twice a day, while on that basis, the patients in observation group were additionally given tiotropium bromide inhalation for 18μg per time, once a day. The two groups were all for a course of treatment for 3 months. The changes of lung function, arterial blood gas parameters and clinical symptom scores of patients in two groups were observed and recorded before and after medical treatment, and the adverse drug reac- tions of the two groups were compared during treatment. Results： After 3 months＇ medical treatment, the FEV1, FEV1 % and FEV1/FVC of patients in two groups rose obviously than before （P 〈0.05 or P 〈0. 01 ）, and the rising rate of FEV1 , FEV1% in observation group was much higher than that in control group （P 〈 0.05 ）. The PaO2 of patients in two groups rose obviously than before, while PaCO2 declined obviously than before （ P 〈 0.05 or P 〈 0. Ol ） , and the improvement rate of patients in observation group was much higher than that in control group （ P 〈 0.05 ）. Meanwhile, CAT scores of patients in two groups declined obviously than before （ P 〈 0.05 or P 〈 0.01 ） , and the declining rate of patients in observation group was much higher than that in control group （ P 〈 0.05 ） . There was no obvious differences appeared of incidence of adverse drug reactions in two groups（P 〉 0.05）. Conclusion： Budesonide/ formoterol combined with tiotropium bromide had coordination effect on the treatment of COPD on the stable phase, which can obviously improve the lung function and clinical symptom with light untoward effect and favorable security.